Small intestinal sampling capsule for inflammatory bowel disease type detection and management.

Area of Science:

• Biomedical Engineering
• Gastroenterology
• Diagnostic Technologies

Background:

• Current fecal biomarkers like lactoferrin and calprotectin aid in distinguishing inflammatory bowel disease (IBD) from irritable bowel syndrome (IBS) but cannot differentiate between Crohn's disease (CD) and ulcerative colitis (UC).
• A key limitation of stool tests is their inability to localize inflammation within the gastrointestinal (GI) tract due to homogenous sample collection.

Purpose of the Study:

• To develop and validate a novel, battery-free smart capsule for targeted, in-situ sampling of inflammatory biomarkers within the small intestine.
• To create a non-invasive tool that complements existing fecal analysis for improved differential diagnosis of IBD subtypes.

Main Methods:

• A pH-sensitive capsule designed to activate in the small intestine's alkaline environment, initiating biomarker sampling.
• Utilized a swelling polyacrylamide hydrogel within the capsule to collect GI fluid and mechanically close the device post-sampling.
• Validated capsule performance using bovine serum albumin (BSA) and calprotectin in vitro and ex vivo studies.

Main Results:

• The smart capsule successfully performed targeted sampling of inflammatory biomarkers in the small intestine.
• Demonstrated consistent and independent biomarker extraction ratios (∼3%) across different sampling matrices in vitro and ex vivo.
• Confirmed the capsule's ability to collect GI fluid and biomarkers for subsequent analysis.

Conclusions:

• The developed smart capsule offers a promising non-invasive method for localized assessment of GI inflammation.
• This technology has the potential to significantly improve differential diagnostics for IBD, enabling more effective treatment strategies.
• The capsule provides a novel approach to analyzing biomarker profiles throughout the digestive tract.